Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly EBITDA Margin of 114.97% for Q3 2025, up 46647.0% year-over-year from N/an in Q3 2024, and up 93.61% quarter-over-quarter from 1797.85% in Q2 2025.
Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' EBITDA Margin history runs 6 years deep, the most recent figure standing at 114.97% for Q3 2025.
- In Q3 2025, EBITDA Margin rose 46647.0% year-over-year to 114.97%; the TTM figure through Sep 2025 stood at 127.25% (up 292687.0% YoY), while the FY2024 annual figure was 181.4%, changed N/A from the prior year.
- EBITDA Margin for Q3 2025 stood at 114.97%, up from 1797.85% in the prior quarter.
- The five-year high for EBITDA Margin was 27.8% in Q4 2024, with the low at 21604.84% in Q1 2021.
- The 4-year median for EBITDA Margin is 1798.77% (2025), against an average of 3505.29%.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin tumbled 1957437 bps in 2021, then soared 1977868 bps in 2022.
- Cyclerion Therapeutics' EBITDA Margin stood at 2690.06% in 2021, then slumped by 63 bps to 4389.87% in 2022, then surged by 101 bps to 27.8% in 2024, then slumped by 514 bps to 114.97% in 2025.
- Business Quant data shows CYCN's EBITDA Margin at 114.97% in Q3 2025, 1797.85% in Q2 2025, and 1798.77% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Cyclerion Therapeutics | 12.51 Mn | 9.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -114.97% |
| Jun 30, 2025 | -1,797.85% |
| Mar 31, 2025 | -1,798.77% |
| Dec 31, 2024 | 27.80% |
| Sep 30, 2024 | -581.44% |
| Jun 30, 2022 | -4,389.87% |
| Mar 31, 2022 | -1,826.16% |
| Dec 31, 2021 | -2,690.06% |
| Sep 30, 2021 | -3,242.82% |
| Jun 30, 2021 | -539.20% |
| Mar 31, 2021 | -21,604.84% |
| Dec 31, 2020 | -14,454.14% |
| Sep 30, 2020 | -5,445.00% |
| Jun 30, 2020 | -2,626.44% |
| Mar 31, 2020 | -2,030.47% |
| Dec 31, 2019 | -1,795.14% |
| Sep 30, 2019 | -2,004.01% |
| Jun 30, 2019 | -2,030.34% |